|
1
|
Qin Y, Gao G, Xie X, Zhu Z, Guan W, Lin X,
Xie Z, Ming O, Chen R, Zhong N, et al: Clinical features and
prognosis of pulmonary Lymphoepithelioma-like carcinoma: Summary of
Eighty-five cases. Clin Lung Cancer. 20:e329–e337. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin Z, Fu S, Zhou Y, Zhang X, Chen C, He
LN, Li H, Wang Y, Chen T, Zhang L and Hong S: First-line
platinum-based chemotherapy and survival outcomes in locally
advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Lung Cancer. 137:100–107. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang J, Lin L, Li W and Guo J: Role of
the ‘inflammation-immunity-abolism’ network in non-small cell lung
cancer: A multi-omics analysis. Discov Oncol. 16:8472025.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen J, Gu C, Chen X, Dai C, Zhao S, Xie
H, Fei K and Chen C: Clinicopathological and prognostic analyses of
86 resected pulmonary lymphoepithelioma-like carcinomas. J Surg
Oncol. 123:544–552. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen M, Chen Y and Fang X: Clinical
features and treatment outcome of lymphoepithelioma-like carcinoma
from multiple primary sites: A population-based, multicentre,
real-world study. BMC Pulm Med. 22:3602022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu Y, Ren S, Liu Y, Han W and Liu W:
Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-review. Onco
Targets Ther. 13:3921–3929. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang M, Li G and Wang Y and Wang Y, Zhao
S, Haihong P, Zhao H and Wang Y: PD-L1 expression in lung cancer
and its correlation with driver mutations: A meta-analysis. Sci
Rep. 7:102552017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sasaki A, Kato T, Ujiie H, Cho Y, Sato M
and Kaji M: Primary pulmonary lymphoepithelioma-like carcinoma with
positive expression of Epstein-Barr virus, PD-L1: A case report.
Int J Surg Case Rep. 79:431–435. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong YM, Yin K, Chen Y, Xie Z, Lv ZY,
Yang JJ, Yang XN, Zhou Q, Wang BC, Zhong WZ, et al: PD-1/PD-L1
combined with LAG3 is associated with clinical activity of immune
checkpoint inhibitors in metastatic primary pulmonary
lymphoepithelioma-like carcinoma. Front Immunol. 13:9518172022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin K, Feng HB, Li LL, Chen Y, Xie Z, Lv
ZY, Guo WB, Lu DX, Yang XN, Yan WQ, et al: Low frequency of
mutation of epidermal growth factor receptor (EGFR) and arrangement
of anaplastic lymphoma kinase (ALK) in primary pulmonary
lymphoepithelioma-like carcinoma. Thorac Cancer. 11:346–352. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sok M, Zavrl M, Greif B and Srpčič M:
Objective assessment of WHO/ECOG performance status. Support Care
Cancer. 10:3793–3798. 2019.PubMed/NCBI
|
|
12
|
Becnel D, Abdelghani R, Nanbo A, Avilala
J, Kahn J, Li L and Lin Z: Pathogenic role of Epstein-Barr virus in
lung cancers. Viruses. 13:8772021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kutob L and Schneider F: Lung cancer
staging. Surg Pathol Clin. 13:57–71. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu YX, Zhang WL, Wang TM, Liao Y, Zhang
YJ, Xiao RW, Jia YJ, Wu ZY, Deng CM, Yang DW, et al: Genomic
landscapes of Epstein-Barr virus in pulmonary
Lymphoepithelioma-Like carcinoma. J Virol. 96:e01693212022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X,
Hou R, Ma W, Liu D, Zheng J, et al: From rough to precise: PD-L1
evaluation for predicting the efficacy of PD-1/PD-L1 blockades.
Front Immunol. 13:9200212022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi M, Sun WL, Hua YY, Han B and Shi L:
Effects of entecavir on hepatitis B virus covalently closed
circular DNA in hepatitis B e antigen-positive patients with
hepatitis B. PLoS One. 10:e01177412015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bégin LR, Eskandari J, Joncas J and
Panasci L: Epstein-Barr virus related lymphoepithelioma-like
carcinoma of lung. J Surg Oncol. 36:280–283. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Samaras MG, Koufopoulos NI, Mitsos S,
Dylja E, Monokrousou A, Tomos P, Panayiotides IG and Goutas D:
Lymphoepithelial carcinoma of the lung: A case report and review of
the literature. Cureus. 16:e703092024.PubMed/NCBI
|
|
19
|
Zhai X, Liu J, Lu D and Zhou Q:
Demographics, clinical features, and prognosis of rare
lymphoepithelioma-like carcinoma across different anatomic sites. J
Egypt Natl Canc Inst. 34:52022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mo Y, Shen J, Zhang Y, Zheng L, Gao F, Liu
L and Xie C: Primary lymphoepithelioma-like carcinoma of the lung:
Distinct computed tomography features and associated clinical
outcomes. J Thorac Imaging. 29:246–251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun X and Kaufman PD: Ki-67: More than a
proliferation marker. Chromosoma. 127:175–186. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Menon SS, Guruvayoorappan C, Sakthivel KM
and Rasmi RR: Ki-67 protein as a tumour proliferation marker. Clin
Chim Acta. 491:39–45. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang L, Zheng J, Fang LJ, Zhang L and
Zhou JY: Efficacy analysis of PD-1/PD-L1 inhibitors in the
treatment of advanced primary pulmonary lymphoepithelioma-like
carcinoma: 6 case reports and literature review. Zhonghua Zhong Liu
Za Zhi. 46:590–594. 2024.(In Chinese). PubMed/NCBI
|
|
24
|
Li L, Ma BBY, Chan ATC, Chan FKL, Murray P
and Tao Q: Epstein-Barr Virus-induced epigenetic pathogenesis of
Viral-associated Lymphoepithelioma-like carcinomas and natural
Killer/T-cell lymphomas. Pathogens. 7:632018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tan B, Xu K, Lyu Y, Liang Y, Liang R, Lei
K, Liang J, Huang J, Wang K, Wu D, et al: Single-cell analysis
reveals transcriptomic features and therapeutic targets in primary
pulmonary lymphoepithelioma-like carcinoma. Commun Biol. 8:3942025.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yin CJ, Wang GJ, Su XM and Li D: Primary
pulmonary lymphoepithelioma-like carcinoma misdiagnosed as lung
squamous cell carcinoma: A case report. World J Clin Cases.
11:7876–7880. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen J, Fan L, Deng H, Li L and Li S:
Neoadjuvant immunochemotherapy-a promising strategy for primary
pulmonary lymphoepithelioma-like carcinoma. World J Surg Oncol.
22:3382024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Yang C, Lv Z, Li J, Li Z, Yuan X, Wu
S, Yuan Y, Cui L, Lu J, et al: Integrating pre- and post-treatment
plasma Epstein-Barr virus DNA levels for better prognostic
prediction of Nasopharyngeal Carcinoma. J Cancer. 9:2715–2722.
2021. View Article : Google Scholar
|
|
29
|
Tang L, Chen N, He W, Zhou J, Zhang J, Lin
Z, Wang Z, Hao J and Lin F: The clinicopathological features and
prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A
systematic review and meta-analysis. PLoS One. 15:e02407292020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou Y, Huang J, Lan J, Hu H, Yuan Z, Dong
L, Deng H, Yue LA, Xiao Y and Yang X: Comparison of first-line
immunotherapy efficacy between advanced lung squamous cell
carcinoma and pulmonary lymphoepithelioma-like carcinoma: A
propensity score matching multicenter study. J Cancer Res Ther.
19:1011–1018. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan
L, Li F, Ding K, Zhou H, Li X, et al: Penpulimab for relapsed or
refractory classical Hodgkin lymphoma: A multicenter, Single-Arm,
pivotal phase I/II Trial (AK105-201). Front Oncol. 12:9252362022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang Z, Pang X, Zhong T, Qu T, Chen N, Ma
S, He X, Xia D, Wang M, Xia M and Li B: Penpulimab, an
Fc-Engineered IgG1 Anti-PD-1 antibody, with improved efficacy and
low incidence of Immune-Related adverse events. Front Immunol.
13:9245422022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaplon H, Chenoweth A, Crescioli S and
Reichert JM: Antibodies to watch in 2022. MAbs. 14:20142962022.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen
G, Zhang L, Huang D, Cang S, Yang Z, et al: Sintilimab plus
platinum and gemcitabine as First-Line treatment for advanced or
metastatic squamous NSCLC: Results from a randomized, Double-blind,
Phase 3 trial (ORIENT-12). J Thorac Oncol. 16:1501–1511. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tamiya Y, Matsumoto S, Zenke Y, Yoh K,
Ikeda T, Shibata Y, Kato T, Nishino K, Nakamura A, Furuya N, et al:
Large-scale clinico-genomic profile of non-small cell lung cancer
with KRAS G12C: Results from LC-SCRUM-Asia study. Lung Cancer.
176:103–111. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCormick F: KRAS as a therapeutic target.
Clin Cancer Res. 21:1797–1801. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He Q, Liu X, Jiang L, Liu P, Xuan W, Wang
Y, Meng R, Feng H, Lv S, Miao Q, et al: First-line treatments for
KRAS-mutant non-small cell lung cancer: Current state and future
perspectives. Cancer Biol Ther. 26:24414992025. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gregorc V, González-Cao M, Salvagni S,
Koumarianou A, Gil-Bazo I, Maio M, Viteri S, Majem M, Gutiérrez V,
Bernabe Caro R, et al: KROCUS: A phase II study investigating the
efficacy and safety of fulzerasib (GFH925) in combination with
cetuximab in patients with previously untreated advanced KRAS G12C
mutated NSCLC. J Clin Oncol. 42:LBA85112024. View Article : Google Scholar
|
|
39
|
Burns TF, Dragnev KH, Fujiwara Y,
Murciano-Goroff YR, Lee DH, Hollebecque A, Koyama T, Cassier PA,
Italiano A, Heist RS, et al: Efficacy and safety of olomorasib
(LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in
combination with pembrolizumab in patients with KRAS G12C-mutant
advanced NSCLC. J Clin Oncol. 42:85102024. View Article : Google Scholar
|
|
40
|
Kuboki Y, Fakih M, Strickler J, Yaeger R,
Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C,
et al: Sotorasib with panitumumab in chemotherapy-refractory
KRASG12C-mutated colorectal cancer: A phase 1b trial. Nat Med.
30:265–270. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang X, Zhou Y, Chen C, Fang W, Cai X,
Zhang X, Zhao M, Zhang B, Jiang W, Lin Z, et al: Hepatitis B virus
reactivation in cancer patients with positive Hepatitis B surface
antigen undergoing PD-1 inhibition. J Immunother Cancer. 7:3222019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen X, Liu T, Mo S, Yang Y, Chen X, Hong
S, Zhou T, Chen G, Zhang Y, Ma Y, et al: A Novel
Inflammation-Marker-Based prognostic model for advanced pulmonary
Lymphoepithelioma-Like carcinoma. J Inflamm Res. 18:2433–2445.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang X, Xiao Y, Zhou Y, Hu H, Deng H,
Huang J, Liang M, Yuan Z, Dong L and Huang S: Efficacy and safety
of immunotherapy in locally advanced or metastatic pulmonary
lymphoepithelioma-like carcinoma: A multicenter retrospective
study. Ther Adv Med Oncol. 17:175883592513160992025. View Article : Google Scholar : PubMed/NCBI
|
